Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

CONCLUSIONS: This unparalleled examination of CD40 therapeutic mechanisms in patients provides insights for design of subsequent clinical trials targeting this pathway.PMID:34112709 | DOI:10.1158/1078-0432.CCR-21-1047

Source: Clinical Cancer Research - June 11, 2021 Category: Cancer & Oncology Authors: Katelyn T Byrne Courtney B Betts Rosemarie Mick Shamilene Sivagnanam David L Bajor Daniel A Laheru E Gabriela Chiorean Mark H O'Hara Shannon M Liudahl Craig W Newcomb Cecile Alanio Ana P Ferreira Byung S Park Takuya Ohtani Austin P Huffman Sara A V äyryn Source Type: research